=>
Uploading C:\Program Files\Stnexp\Queries\10584662a.str



chain nodes :
7 8 9 10 16 23 24 25
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 17 18 19 20 21 22
chain bonds :
2-25 5-7 7-8 8-9 9-10 9-16 10-11 16-17 18-24 22-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-15 12-13 13-14 14-15 17-18 17-22 18-19
19-20 20-21 21-22
exact/norm bonds :
9-16 10-11 11-12 11-15 12-13 13-14 14-15 16-17
exact bonds :
2-25 5-7 7-8 8-9 9-10 18-24 22-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:Atom 23:CLASS 24:CLASS 25:CLASS

L3 STRUCTURE UPLOADED

=> d
L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l3 full
FULL SEARCH INITIATED 16:30:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       53 TO ITERATE

100.0% PROCESSED       53 ITERATIONS                              16 ANSWERS
SEARCH TIME: 00.00.01

L4           16 SEA SSS FUL L3

=> d l4 1-16

L4   ANSWER 1 OF 16  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   1004792-26-0  REGISTRY
ED   Entered STN:  20 Feb 2008
CN   1H-Imidazolium, 1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-3-
     [4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-  (CA INDEX NAME)
MF   C34 H40 Cl3 N2 O S
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL
```

PAGE 1-A



PAGE 2-A



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 2 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 724755-64-0 REGISTRY
ED Entered STN: 10 Aug 2004
CN 2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4-methyl-, compd. with 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-1H-imidazole (1:1) (CA INDEX NAME)
OTHER NAMES:
CN Butoconazole ciclopirox
MF C19 H17 Cl3 N2 S . C12 H17 N O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 64872-76-0
CMF C19 H17 Cl3 N2 S



CM 2

CRN 29342-05-0
CMF C12 H17 N O2



4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 3 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 151909-77-2 REGISTRY
ED Entered STN: 23 Dec 1993
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, (R)-, mononitrate (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (-)-Butoconazole nitrate
FS STEREOSEARCH
MF C19 H17 Cl3 N2 S . H N O3
SR CA
LC STN Files: CA, CAPLUS, CASREACT, PROMT

CM 1

CRN 151909-76-1
CMF C19 H17 Cl3 N2 S

Absolute stereochemistry.



CM 2

CRN 7697-37-2
CMF H N O3



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 4 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 151909-76-1 REGISTRY
ED Entered STN: 23 Dec 1993
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, (R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H17 Cl3 N2 S
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 5 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 151909-75-0 REGISTRY
ED Entered STN: 23 Dec 1993
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, (S)-, mononitrate (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (+)-Butoconazole nitrate
FS STEREOSEARCH
MF C19 H17 Cl3 N2 S . H N O3
SR CA
LC STN Files: CA, CAPLUS, CASREACT

CM 1

CRN 151909-74-9
CMF C19 H17 Cl3 N2 S

Absolute stereochemistry.



CM 2

CRN 7697-37-2
CMF H N O3



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 6 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 151909-74-9 REGISTRY
ED Entered STN: 23 Dec 1993

CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, (S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H17 Cl3 N2 S
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 7 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 124588-39-2 REGISTRY
ED Entered STN: 05 Jan 1990
CN 1-Naphthalenemethanamine, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-N-methyl-, mixt. with 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-1H-imidazole (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Naphthalenemethanamine, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-N-methyl-, mixt. with (±)-1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-1H-imidazole
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, (±)-, mixt. contg.
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, mixt. contg. (9CI)
MF C23 H27 N . C19 H17 Cl3 N2 S
CI MXS
SR CA
LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL

CM 1

CRN 101828-21-1
CMF C23 H27 N



CM 2

CRN 64872-76-0
CMF C19 H17 Cl3 N2 S



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 8 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 82382-24-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, nitrate (9CI) (CA INDEX NAME)
MF C19 H17 Cl3 N2 S . x H N O3
LC STN Files: CA, CAPLUS, CHEMINFORMRX, IMSPATENTS, IMSRESEARCH

CM 1

CRN 64872-76-0
CMF C19 H17 Cl3 N2 S



CM 2

CRN 7697-37-2
CMF H N O3



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 9 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 69061-38-7 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]-2-methylbutyl]-, compd. with nitric acid (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]-2-methylbutyl]-, mononitrate (9CI)
MF C20 H19 Cl3 N2 S . H N O3
LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, TOXCENTER, USPATFULL

CM 1

CRN 69061-37-6
CMF C20 H19 Cl3 N2 S



CM 2

CRN 7697-37-2
CMF H N O3



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 10 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 69061-37-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]-2-methylbutyl]- (CA INDEX NAME)
MF C20 H19 Cl3 N2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 11 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 68056-02-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,3,6-trichlorophenyl)thio]butyl]-, compd. with nitric acid (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,3,6-trichlorophenyl)thio]butyl]-, mononitrate (9CI)
MF C19 H16 Cl4 N2 S . H N O3
LC STN Files: CA, CAPLUS, TOXCENTER

CM 1

CRN 68056-01-9
CMF C19 H16 Cl4 N2 S



CM 2

CRN 7697-37-2
CMF H N O3



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 12 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 68056-01-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,3,6-trichlorophenyl)thio]butyl]- (CA INDEX NAME)
MF C19 H16 Cl4 N2 S
CI COM
LC STN Files: BEILSTEIN*

(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 ANSWER 13 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 68055-96-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,4,6-trichlorophenyl)thio]butyl]-, compd. with nitric acid (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,4,6-trichlorophenyl)thio]butyl]-, mononitrate (9CI)
MF C19 H16 Cl4 N2 S . H N O3
LC STN Files: CA, CAPLUS, TOXCENTER

CM 1

CRN 68055-95-8
CMF C19 H16 Cl4 N2 S



CM 2

CRN 7697-37-2
CMF H N O3



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 14 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 68055-95-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,4,6-trichlorophenyl)thio]butyl]-
(CA INDEX NAME)
MF C19 H16 Cl4 N2 S
CI COM
LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXCENTER
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 15 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 64872-77-1 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-,
nitrate (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-,
(±)-, mononitrate
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-,

mononitrate (9CI)
OTHER NAMES:
CN (±)-Butoconazole nitrate
CN Butaconazole nitrate
CN Butoconazole nitrate
CN Femstat
CN Gynomyk
CN RS 35887
CN RS 35887-00-10-3
DR 67085-14-7
MF C19 H17 Cl3 N2 S . H N O3
LC STN Files: BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CIN, CSCHEM, EMBASE, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

CM 1

CRN 64872-76-0
CMF C19 H17 Cl3 N2 S



CM 2

CRN 7697-37-2
CMF H N O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

60 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
61 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 16 OF 16 REGISTRY COPYRIGHT 2009 ACS on STN
RN 64872-76-0 REGISTRY
ED Entered STN: 16 Nov 1984

CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-
    (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-,
    (±)-
OTHER NAMES:
CN Butaconazole
CN Butoconazole
DR 67085-13-6, 85496-23-7
MF C19 H17 Cl3 N2 S
CI COM
LC STN Files: ADISNEWS, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS,
      CASREACT, CHEMCATS, DDFU, DRUGU, EMBASE, IFICDB, IFIUDB, IMSPATENTS,
      IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS,
      SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
        (*File contains numerically searchable property data)
    Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

            214 REFERENCES IN FILE CA (1907 TO DATE)
              4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
            215 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s l1 and nitrate
COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID
The query entered contains both search terms created by
structure-building or screen commands and text search terms. L#s
created via the STRUCTURE or SCREEN commands must be searched in the
structures files separately from text terms or profiles. The L#
answer sets from structure searches can be used in crossover searches
and can be combined with text terms.

=> end
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:n

=>
=> file caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                   ENTRY   SESSION

FULL ESTIMATED COST 421.84 422.06

FILE 'CAPLUS' ENTERED AT 16:51:41 ON 23 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Apr 2009 VOL 150 ISS 17
FILE LAST UPDATED: 22 Apr 2009 (20090422/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l4
L5         276 L4

=> s l5 and nitrate and ?pur?
        297621 NITRATE
         89304 NITRATES
        346712 NITRATE
                (NITRATE OR NITRATES)
       2407569 ?PUR?
L6          16 L5 AND NITRATE AND ?PUR?

=> d l6 1-16 ibib abs hitstr
```

L6 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:391361 CAPLUS <<LOGINID::20090423>>
TITLE: Colloidal nanodispersion compositions comprising lipophilic active compounds and method for their preparation
INVENTOR(S): Temtsin Krayz, Galia; Averbuch, Maryana; Gitis, Larisa; Zelkind, Ilya
PATENT ASSIGNEE(S): Solubest Ltd, Israel
SOURCE: PCT Int. Appl., 97pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2009040818 A1 20090402 WO 2008-IL1294 20080925
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
US 20090098200 A1 20090416 US 2008-238424 20080925
PRIORITY APPLN. INFO.: US 2007-975045P P 20070925
US 2007-975066P P 20070925

AB The present invention relates to compns. comprising a lipophilic active compound, e.g., a human or veterinary drug or a nutraceutical, interwoven with a polymeric matrix formed by two or more polymers, wherein one of the polymers is an amphiphilic polymer and the other polymer is either an amphiphilic polymer with a different hydrophobic-hydrophilic balance or a hydrophilic polymer, and the active lipophilic compound has modified physicochem. properties. The composition forms colloidal nanodispersion upon contact with aqueous media.

IT 64872-77-1, Butoconazole nitrate
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(colloidal nanodispersion compns. comprising lipophilic active compds. and method for their preparation)

RN 64872-77-1 CAPLUS
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 64872-76-0
CMF C19 H17 Cl3 N2 S



CM 2

CRN 7697-37-2
CMF H N O3



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1157521 CAPLUS <<LOGINID::20090423>>
DOCUMENT NUMBER: 149:386603
TITLE: Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof as cancer chemopreventive agents
INVENTOR(S): Fortin, Samuel
PATENT ASSIGNEE(S): Centre de Recherche sur les biotechnologies marines, Can.
SOURCE: PCT Int. Appl., 95pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008113177	A1	20080925	WO 2008-CA530	20080319

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-895795P P 20070320
OTHER SOURCE(S): CASREACT 149:386603; MARPAT 149:386603
AB There are provided various compds. and compns. comprising polyunsatd. fatty acid monoglycerides and derivs. thereof. These compds. and compns. can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability. Thus, in order to determine the solubility of various compds. in a fish oil as compared to their solubility in compns. of the invention (bis-demethoxycurcumin, demetoxycurcumin, curcumin and total curcuminoids), a first sample of turmeric oleoresin (100 mg) obtained from ethanol extraction was stirred at room temperature in a fish oil (1.0 g) for 30 min; then another sample of turmeric oleoresin (100 mg) was stirred at room temperature in composition of the invention (1.0 g) for 30 min; both resulting suspensions were centrifuged at 12 000 rpm for 5 min and 10 μl of each supernatant was dissolved in DMSO and further dilution was made to meet the linearity range of HPLC/MS method for the quantification of curcuminoids (0.001 μg/mL to 0.1 μg/mL).
IT 64872-76-0, Butoconazole

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising polyunsatd. fatty acid monoglycerides or derivs. thereof and uses thereof)

RN 64872-76-0 CAPLUS

CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1450137 CAPLUS <<LOGINID::20090423>>

DOCUMENT NUMBER: 148:62071

TITLE: Anti-infection augmentation foamable compositions and kit and uses thereof

INVENTOR(S): Tamarkin, Dov; Friedman, Doron; Eini, Meir

PATENT ASSIGNEE(S): Foamix Ltd., Israel

SOURCE: U.S. Pat. Appl. Publ., 43pp., Cont.-in-part of U.S. Ser. No. 448,490.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 33

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070292355	A1	20071220	US 2007-732547	20070404
WO 2004037225	A2	20040506	WO 2003-IB5527	20031024
WO 2004037225	A3	20041229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050031547	A1	20050210	US 2004-835505	20040428
US 20050069566	A1	20050331	US 2004-911367	20040804
US 20050074414	A1	20050407	US 2004-922358	20040820
AU 2004313285	A1	20050929	AU 2004-313285	20041216
US 20050186142	A1	20050825	US 2005-41921	20050124

ZA 2005003298 A 20060830 ZA 2005-3298 20050425
US 20060140984 A1 20060629 US 2005-532618 20051222
AU 2006201878 A1 20070927 AU 2006-201878 20060504
US 20060269485 A1 20061130 US 2006-448490 20060607
AU 2006339311 A2 20070907 AU 2006-339311 20060607
AU 2006339311 A1 20070907
CA 2611577 A1 20070907 CA 2006-2611577 20060607
WO 2007099396 A2 20070907 WO 2006-IB3975 20060607
WO 2007099396 A3 20080313
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
EP 1919449 A2 20080514 EP 2006-847249 20060607
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS
US 20070280891 A1 20071206 US 2006-645444 20061226
US 20080050317 A1 20080228 US 2007-894668 20070820
WO 2008152444 A2 20081218 WO 2007-IB4628 20071129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
IN 2007KN04925 A 20080704 IN 2007-KN4925 20071218

PRIORITY APPLN. INFO.:

IL 2002-152486	A	20021025
US 2002-429546P	P	20021129
US 2003-492385P	P	20030804
US 2003-497648P	P	20030825
WO 2003-IB5527	W	20031024
US 2003-530015P	P	20031216
US 2004-835505	A2	20040428
US 2004-911367	A2	20040804
US 2004-922358	A2	20040820
US 2005-41921	A2	20050124
US 2005-688244P	P	20050607
US 2005-532618	A2	20051222
US 2006-789186P	P	20060404
US 2006-448490	A2	20060607
US 2006-861620P	P	20061129
US 2007-880434P	P	20070112
WO 2006-IB3975	W	20060607

AB This invention relates to anti-infective foamable composition and kits include a foamable carrier; a therapeutically safe and effective concentration of an anti-infective agent; an augmenting agent selected from the group

consisting of a keratolytic agent and a skin penetration enhancer; and a propellant. The composition is housed in a container and upon release is expandable to form a breakable foam. The foamable carrier is selected to generate a foam of good or excellent quality in the presence of the augmenting agent and anti-infective agent. Methods for treating, alleviating or preventing a disorder of the skin, a body cavity or mucosal surface, wherein the disorder involves a fungal, bacterial, or viral infection as one of its etiol. factors, is described. Thus, foamable composition was prepared containing PEG 400 91.65%, hydroxypropyl cellulose 0.475,
steareth 2 1.88%, salicylic acid 5.0%, and ciclopiroxolamine 1.0%.

IT 64872-76-0, Butoconazole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-infection augmentation foamable compns. and kit and uses thereof)

RN 64872-76-0 CAPLUS

CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]- (CA INDEX NAME)



L6 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1016569 CAPLUS <<LOGINID::20090423>>

DOCUMENT NUMBER: 148:503081

TITLE: Novel drug delivery system

INVENTOR(S): Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh Singh; Gupta, Vinod Kumar

PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India

SOURCE: Indian Pat. Appl., 80pp., Addn. of Indian Appl. No. 2004MU198.
CODEN: INXXBQ

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2005MU01012	A	20070831	IN 2005-MU1012	20050826
PRIORITY APPLN. INFO.:			IN 2004-MU198	A0 20040220

AB A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise addnl. another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

IT 64872-77-1, Butoconazole Nitrate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel drug delivery system)
RN 64872-77-1 CAPLUS
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 64872-76-0
CMF C19 H17 Cl3 N2 S



CM 2

CRN 7697-37-2
CMF H N O3



L6 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:769872 CAPLUS <<LOGINID::20090423>>
DOCUMENT NUMBER: 148:387155
TITLE: Novel dosage form
INVENTOR(S): Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh Singh; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India
SOURCE: Indian Pat. Appl., 96pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2005MU01013	A	20070629	IN 2005-MU1013	20050826
PRIORITY APPLN. INFO.:			IN 2005-MU1013	20050826

AB A dosage form comprising of a high-dose, high-solubility active ingredient for modified release and a low-dose active ingredient for immediate release

wherein the weight ratio of immediate-release active ingredient and modified-release active ingredient is from 1:10 to 1:15000 and the weight of modified-release active ingredient per unit is from 500 mg to 1500 mg. A process for preparing the dosage form is provided.

IT 64872-77-1, Butoconazole Nitrate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form containing modified-release and immediate-release active ingredients)

RN 64872-77-1 CAPLUS

CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 64872-76-0
CMF C19 H17 Cl3 N2 S



CM 2

CRN 7697-37-2
CMF H N O3



L6 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:412735 CAPLUS <<LOGINID::20090423>>
DOCUMENT NUMBER: 147:45730
TITLE: Inhibition of angiogenesis by the antifungal drug itraconazole
AUTHOR(S): Chong, Curtis R.; Xu, Jing; Lu, Jun; Bhat, Shridhar; Sullivan, David J., Jr.; Liu, Jun O.
CORPORATE SOURCE: Dep. Pharmacology Molecular Sci., The Johns Hopkins Univ. Sch. Med., Baltimore, MD, 21205, USA
SOURCE: ACS Chemical Biology (2007), 2(4), 263-270
CODEN: ACBCCT; ISSN: 1554-8929
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

OTHER SOURCE(S): CASREACT 147:45730

AB Angiogenesis, the formation of new blood vessels, is implicated in a number of important human diseases, including cancer, diabetic retinopathy, and rheumatoid arthritis. To identify clin. useful angiogenesis inhibitors, the authors assembled and screened a library of mostly Food and Drug Administration-approved drugs for inhibitors of human endothelial cell proliferation. One of the most promising and unexpected this was itraconazole, a known antifungal drug. Itraconazole inhibits endothelial cell cycle progression at the G1 phase in vitro and blocks vascular endothelial growth factor/basic fibroblast growth factor-dependent angiogenesis in vivo. In attempts to delineate the mechanism of action of itraconazole the authors found that human lanosterol 14α-demethylase (14DM) is essential for endothelial cell proliferation and may partially mediate the inhibition of endothelial cells by itraconazole. Together, these findings suggest that itraconazole has the potential to serve as an antiangiogenic drug and that lanosterol 14DM is a promising new target for discovering new angiogenesis inhibitors.

IT 64872-76-0, Butoconazole
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of angiogenesis by antifungal drug itraconazole)

RN 64872-76-0 CAPLUS

CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]- (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1256641 CAPLUS <<LOGINID::20090423>>

DOCUMENT NUMBER: 146:50262

TITLE: Antibiotic kit and compositions

INVENTOR(S): Friedman, Doron; Besonov, Alex; Tamarkin, Dov; Eini, Meir

PATENT ASSIGNEE(S): Foamix Ltd., Israel

SOURCE: U.S. Pat. Appl. Publ., 31pp., Cont.-in-part of U.S. Ser. No. 532,618.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 33

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US	20060269485	A1	20061130	US 2006-448490	20060607
WO	2004037225	A2	20040506	WO 2003-IB5527	20031024
WO	2004037225	A3	20041229		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US	20050069566	A1	20050331	US 2004-911367	20040804
US	20060140984	A1	20060629	US 2005-532618	20051222
AU	2006339311	A2	20070907	AU 2006-339311	20060607
AU	2006339311	A1	20070907		
CA	2611577	A1	20070907	CA 2006-2611577	20060607
WO	2007099396	A2	20070907	WO 2006-IB3975	20060607
WO	2007099396	A3	20080313		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP	1919449	A2	20080514	EP 2006-847249	20060607

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

US	20070292355	A1	20071220	US 2007-732547	20070404
WO	2008075207	A2	20080626	WO 2007-IB4459	20070404
WO	2008075207	A3	20090129		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

IN	2007KN04925	A	20080704	IN 2007-KN4925	20071218

PRIORITY APPLN. INFO.:

US 2002-429546P	P	20021129
US 2003-492385P	P	20030804
WO 2003-IB5527	W	20031024
US 2004-911367	A2	20040804
US 2005-688244P	P	20050607
US 2005-532618	A2	20051222
IL 2002-152486	A	20021025
US 2003-497648P	P	20030825
US 2003-530015P	P	20031216

US 2004-835505	A2	20040428
US 2004-922358	A2	20040820
US 2005-41921	A2	20050124
US 2006-789186P	P	20060404
US 2006-448490	A2	20060607
WO 2006-IB3975	W	20060607
US 2006-861620P	P	20061129
US 2007-880434P	P	20070112

AB The present invention relates to a therapeutic kit to provide an effective dosage of an antibiotic including an aerosol packaging assembly. The assembly includes a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition of an antibiotic; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixts. at 2-50%, a surfactant, 0.01-5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at 3-25% by weight of the total composition

IT 64872-76-0, Butoconazole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibiotic kit and compns.)

RN 64872-76-0 CAPLUS

CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]- (CA INDEX NAME)



L6 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:633682 CAPLUS <<LOGINID::20090423>>

DOCUMENT NUMBER: 145:110319

TITLE: Topical compositions and kits for treating irritation

INVENTOR(S): Evans, Celeste; Russell, Meghan; Weiss, Daniel

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060137684	A1	20060629	US 2005-285811	20051123
AU 2005311931	A1	20060608	AU 2005-311931	20051201
CA 2588710	A1	20060608	CA 2005-2588710	20051201

WO 2006060462 A1 20060608 WO 2005-US43284 20051201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1833539 A1 20070919 EP 2005-852505 20051201
R: DE, ES, GB, IT, NL
MX 2007006556 A 20070911 MX 2007-6556 20070601
PRIORITY APPLN. INFO.: US 2004-632151P P 20041201
WO 2005-US43284 W 20051201

AB This invention relates to methods, compns., kits and treatment regimens for applying active ingredients to the groin area of an individual to treat the symptoms of a vaginal or vulvar condition using a spray applicator. The active ingredient is selected from a local anesthetic, an antihistamine, an anti-inflammatory agent, an antifungal agent, an antibiotic, an antiviral agent, and a skin protectant. Thus, a liquid spray with antihistamine contained diphenhydramine HCl 2%, zinc acetate 0.1%, alc. 12%, glycerin 2%, povidone 1%, and water 82.9%.

IT 64872-76-0, Butaconazole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical compns. and kits for treating skin irritation)

RN 64872-76-0 CAPLUS

CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]- (CA INDEX NAME)



L6 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:100738 CAPLUS <<LOGINID::20090423>>
DOCUMENT NUMBER: 144:198849
TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients
INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060024365	A1	20060202	US 2005-134633	20050519
IN 2002MU00697	A	20040529	IN 2002-MU697	20020805
IN 193042	A1	20040626		
IN 2002MU00699	A	20040529	IN 2002-MU699	20020805
IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
US 20040096499	A1	20040520	US 2003-630446	20030729

PRIORITY APPLN. INFO.:

IN 2002-MU697	A	20020805
IN 2002-MU699	A	20020805
IN 2003-MU80	A	20030122
IN 2003-MU82	A	20030122
US 2003-630446	A2	20030729

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

IT 64872-77-1, Butoconazole nitrate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release active ingredients)

RN 64872-77-1 CAPLUS
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 64872-76-0
CMF C19 H17 Cl3 N2 S



CM 2

CRN 7697-37-2
CMF H N O3



L6 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:729555 CAPLUS <<LOGINID::20090423>>
DOCUMENT NUMBER: 143:199864
TITLE: Vaginal compositions for treating infections
INVENTOR(S): Ahmad, Nawaz; Patel, Kalpana J.; Wiita, Brinda
PATENT ASSIGNEE(S): Mcneil-Ppc, Inc., USA
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005072774	A1	20050811	WO 2005-US976		20050113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20050222169	A1	20051006	US 2005-34289		20050112
AU 2005209175	A1	20050811	AU 2005-209175		20050113
CA 2553390	A1	20050811	CA 2005-2553390		20050113
EP 1703919	A1	20060927	EP 2005-711381		20050113
R: DE, ES, FR, GB, IT					
CN 1913922	A	20070214	CN 2005-80002530		20050113
BR 2005006898	A	20070612	BR 2005-6898		20050113
JP 2007534661	T	20071129	JP 2006-549568		20050113
MX 2006008155	A	20071018	MX 2006-8155		20060717
KR 2007034984	A	20070329	KR 2006-716402		20060816
PRIORITY APPLN. INFO.:			US 2004-537154P	P	20040116
			US 2005-34289	A	20050112
			WO 2005-US976	W	20050113

AB This invention relates to methods, compns. and treatment regimens for applying cooling active ingredients to the perineum of a woman to treat the symptoms of a vaginal or vulvar infection or vulvar pain in order to speed the woman's relief from pain and/or itch. Thus, a gel contained 70% EtOH 5.00, propylene glycol 5.00, sorbitol solution 5.00, hydroxyethyl cellulose 1.50, and water 83.50%.
IT 64872-76-0, Butaconazole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vaginal compns. for treating infections)
RN 64872-76-0 CAPLUS
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:696883 CAPLUS <<LOGINID::20090423>>
DOCUMENT NUMBER: 143:194001
TITLE: A preparation of high-purity butoconazole nitrate with specified particle size, useful as antifungal agent
INVENTOR(S): Czibula, Laszlo; Dobay, Laszlo; Werk Papp, Eva; Nagy Bagdy, Judit; Sebok, Ferenc
PATENT ASSIGNEE(S): Richter Gedeon Vegyeszeti Gyar Rt., Hung.
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070897	A1	20050804	WO 2005-HU2	20050125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
HU 2004270	A3	20070928	HU 2004-270	20040127
EP 1709005	A1	20061011	EP 2005-702171	20050125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
JP 2007519699	T	20070719	JP 2006-550311	20050125
EP 1903035	A2	20080326	EP 2007-23914	20050125
EP 1903035	A3	20090107		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, MK, YU, RS				

US 20080221190	A1	20080911	US 2006-584662		20060626
NO 2006003805	A	20060825	NO 2006-3805		20060825
PRIORITY APPLN. INFO.:			HU 2004-270	A	20040127
			EP 2005-702171	A3	20050125
			WO 2005-HU2	W	20050125

OTHER SOURCE(S): CASREACT 143:194001

GI



I



II

AB The invention relates to a preparation of high-purity butoconazole nitrate (I•HNO3) containing maximum 0.1 weight% of chemical impurities, wherein at least 95% of the particles of the substance are below 75μm by diameter, whereas at least 99% of the particles are below 250μm by diameter, and process for its preparation Butoconazole nitrate was prepared via S-alkylation of 2,6-dichloro-thiophenol by butanol derivative II and subsequent salt formation with an overall yield of 90%.

IT 64872-76-0P, Butoconazole 64872-77-1P, Butoconazole nitrate
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of high-purity butoconazole nitrate with specified particle size useful as antifungal agent)

RN 64872-76-0 CAPLUS

CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]- (CA INDEX NAME)



RN 64872-77-1 CAPLUS
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 64872-76-0
CMF C19 H17 Cl3 N2 S



CM 2

CRN 7697-37-2
CMF H N O3



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1036401 CAPLUS <<LOGINID::20090423>>
DOCUMENT NUMBER: 142:28149
TITLE: Foamable pharmaceutical compositions for the dermatol. administration of corticosteroids and antifungal

agents
INVENTOR(S): Popp, Karl F.; Yuhas, Edward R.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 33 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040241099	A1	20041202	US 2003-445487	20030528
US 7186416	B2	20070306		
AU 2004242963	A1	20041209	AU 2004-242963	20040527
CA 2527499	A1	20041209	CA 2004-2527499	20040527
WO 2004105702	A2	20041209	WO 2004-US16733	20040527
WO 2004105702	A3	20050506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1633368	A2	20060315	EP 2004-753550	20040527
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004010721	A	20060620	BR 2004-10721	20040527
CN 1794998	A	20060628	CN 2004-80014404	20040527
JP 2007500235	T	20070111	JP 2006-533458	20040527
KR 2006023972	A	20060315	KR 2005-722487	20051124
MX 2005012842	A	20060517	MX 2005-12842	20051128
IN 2005MN01366	A	20060519	IN 2005-MN1366	20051206
ZA 2005010388	A	20061227	ZA 2005-10388	20051221
US 20070059253	A1	20070315	US 2006-595864	20061113

PRIORITY APPLN. INFO.: US 2003-445487 A 20030528
WO 2004-US16733 W 20040527

OTHER SOURCE(S): MARPAT 142:28149

AB Novel pharmaceutical compns. comprising a foamable delivery system are provided for the dermatol. administration of corticosteroids and antifungal agents. While the novel compns. and foamable drug delivery system may be utilized for administration of a wide variety of drugs to epithelial tissues, to treat a wide variety of diseases, disorders, or conditions, the inventive compns. and foamable drug delivery systems are particularly useful for the dermatol. administration of corticosteroids and antifungal agents. Thus, a formulation contained clobetasol propionate 0.05, Poloxamer-188 1.60, citric acid buffer 0.15, EtOH 60.0, Polysorbate-60 0.10, propylene glycol 2.00, water 31.6, and propellant (Propane-Isobutane) 4.50%.

IT 64872-77-1, Butoconazole nitrate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(foamable pharmaceutical compns. for dermatol. administration of corticosteroids and antifungal agents)

RN 64872-77-1 CAPLUS

CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 64872-76-0
CMF C19 H17 Cl3 N2 S



CM 2

CRN 7697-37-2
CMF H N O3



REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:550533 CAPLUS <<LOGINID::20090423>>
DOCUMENT NUMBER: 141:82297
TITLE: Immunostimulatory nucleic acids for the treatment of disorders associated with microorganisms, for preventing antibiotic resistance and for treating and preventing warts
INVENTOR(S): Bratzler, Robert L.; Petersen, Deanna M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 54 pp., Cont. of U.S. Ser. No. 801,839, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20040131628	A1	20040708	US 2003-666733		20030919
PRIORITY APPLN. INFO.:			US 2000-187834P	P	20000308
			US 2001-801839	B1	20010308

OTHER SOURCE(S): MARPAT 141:82297

AB The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an antimicrobial agent for the treatment or prevention of infectious disease associated with microorganisms in subjects, for preventing antibiotic resistance and for treating and preventing warts. The combination of drugs are administered in synergistic amts. or in various dosages or at various time schedules. The invention also relates to kits and compns. concerning the combination of drugs.

IT 64872-77-1, Butoconazole Nitrate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunostimulatory nucleic acids for treatment of disorders associated with microorganisms, preventing antibiotic resistance, and treating and preventing warts, and use with other agents)

RN 64872-77-1 CAPLUS

CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 64872-76-0
CMF C19 H17 Cl3 N2 S



CM 2

CRN 7697-37-2
CMF H N O3



L6 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:41226 CAPLUS <<LOGINID::20090423>>
DOCUMENT NUMBER: 140:105321
TITLE: Methods and compositions relating to isoleucine boroproline compounds
INVENTOR(S): Adams, Sharlene; Miller, Glenn T.; Jesson, Michael I.; Jones, Barry
PATENT ASSIGNEE(S): Point Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 152 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004658	A2	20040115	WO 2003-US21405	20030709
WO 2004004658	A3	20050804		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491466	A1	20040115	CA 2003-2491466	20030709
AU 2003265264	A1	20040123	AU 2003-265264	20030709
US 20040077601	A1	20040422	US 2003-616694	20030709
US 20050084490	A1	20050421	US 2003-616409	20030709
EP 1578434	A2	20050928	EP 2003-763380	20030709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006507352	T	20060302	JP 2004-562634	20030709
CN 1802090	A	20060712	CN 2003-821282	20030709
CN 1826129	A	20060830	CN 2003-821281	20030709
IN 2005KN00151	A	20050916	IN 2005-KN151	20050208

PRIORITY APPLN. INFO.:	US 2002-394856P	P	20020709
	US 2002-414978P	P	20021001
	US 2003-466435P	P	20030428
	WO 2003-US21405	W	20030709

OTHER SOURCE(S): MARPAT 140:105321

AB A method for treating subjects with, inter alia, abnormal cell proliferation or infectious disease using agents of formula (I, AmNHCH(CH(CH3)CH2CH3)COA1R) (where Am and A1 are amino acids and R = organo boronates, organo phosphonates, fluoroalkyl ketones, alphaketos, N-peptiolyl-O-(acylhydroxylamines), azapeptides, azetidines, fluoroolefins dipeptide isosteres, peptidyl (α-aminoalkyl) phosphonate esters, aminoacyl pyrrolidine-2-nitriles and 4-cyanothiazolidides) is claimed. Methods for stimulating an immune response using the compds. of the invention are also claimed. Compns. containing Ile-boroPro compds. are also provided as are kits containing the compns. The invention embraces the use of these compds. alone or in combination with other therapeutic agents.

IT 64872-77-1, Butoconazole nitrate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic methods and compns. relating to isoleucine boroproline compds. alone or in combination with other drugs, antibodies, or antigens)

RN 64872-77-1 CAPLUS
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 64872-76-0
CMF C19 H17 Cl3 N2 S



CM 2

CRN 7697-37-2
CMF H N O3



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:3366 CAPLUS <<LOGINID::20090423>>
DOCUMENT NUMBER: 130:57017
TITLE: Powder-based skin spray
INVENTOR(S): Vandamme, Patricia Liliane; Coremans, Gerrit Alfons
PATENT ASSIGNEE(S): N.V. Nutricia, Neth.
SOURCE: Eur. Pat. Appl., 6 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 884043	A1	19981216	EP 1998-201677	19980520
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NL 1006103	C2	19981125	NL 1997-1006103	19970521
PRIORITY APPLN. INFO.:			NL 1997-1006103 A	19970521

AB A spray for skin hygiene and/or cosmetic purposes is based on a spray powder comprising: an essentially sealed pressurized container provided with means for the controlled delivery of the spray powder from the container; a spray powder that comprises ≥1 active compound that is suitable for skin hygiene and/or cosmetic purposes, the particle size of said compound being such that ≥10% by weight of the particles are >10 μm; ≥1 hydrofluoroalkane propellant gas; and optional further carriers and/or additives for skin sprays. The active

compound is preferably an imidazole and/or allylamine derivative, in particular miconazole or econazole or their salts. The propellant gas is preferably HFA 134a, HFA 152a, or HFA 123a.

IT 64872-76-0, Butoconazole
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(powder-based skin spray)

RN 64872-76-0 CAPLUS

CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:30715 CAPLUS <<LOGINID::20090423>>

DOCUMENT NUMBER: 120:30715

ORIGINAL REFERENCE NO.: 120:5801a,5804a

TITLE: The synthesis and antifungal activity of the enantiomers of butoconazole nitrate

AUTHOR(S): Rotstein, David M.; Walker, Keith A. M.

CORPORATE SOURCE: Syntex Res., Palo Alto, CA, 94304, USA

SOURCE: Tetrahedron: Asymmetry (1993), 4(7), 1521-6
CODEN: TASYE3; ISSN: 0957-4166

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 120:30715

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The S and R enantiomers I and II of the antifungal agent butoconazole nitrate have been prepared in optically pure form, in three steps, from R- and S-glycidyl tosylates III and IV, resp. No significant difference was found in the in vitro activity of butoconazole and its enantiomers vs. Candida albicans.

IT 64872-77-1P, (±)-Butoconazole nitrate
RL: PREP (Preparation)
(enantiomers of, stereoselective total synthesis of)

RN 64872-77-1 CAPLUS

CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-,

nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 64872-76-0
CMF C19 H17 Cl3 N2 S



CM 2

CRN 7697-37-2
CMF H N O3



IT 151909-75-0P, (+)-Butoconazole nitrate
    151909-77-2P, (-)-Butoconazole nitrate
    RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
    (stereoselective total synthesis of)
RN 151909-75-0 CAPLUS
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-,
    (S)-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 151909-74-9
CMF C19 H17 Cl3 N2 S

Absolute stereochemistry.



CM 2

CRN 7697-37-2
CMF H N O3



RN 151909-77-2 CAPLUS
CN 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, (R)-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 151909-76-1
CMF C19 H17 Cl3 N2 S

Absolute stereochemistry.



CM 2

CRN 7697-37-2
CMF H N O3